Tallimustine

Tallimustine (FCE 24517), a distamycin-A derivative, is an anticancer agent[1][2][4].

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

Tallimustine (0.1-10 μM, 4 h) induces damage to purified SV40 DNA[1]. Tallimustine (72 h ) shows cytotoxicity in CEM Cells, with an IC50 of 3.5 nM[1]. Tallimustine (25 and 100 nM, 6 days) induces erythroid differentiation of K562 cells[2]. Tallimustine (100 nM, 6 days) increases accumulation of γ-globin mRNA in K562 cells[2]. Tallimustine (0.5 μg/mL, 1 h) arrests SW626 cells in G2/M phase[3]. Cell Viability Assay[2] Cell Line: K562 cells Concentration: 25 and 100 nM Incubation Time: 4 days Result: Inhibited cell proliferation.

Tallimustine (3 mg/kg, i.p.) shows antileukaemic activity in L1210 tumor bearing mice[4]. Animal Model: L1210 tumor bearing mice[2]. Dosage: 3 mg/kg Administration: Intraperitoneal injection (i.p.) Result: Prolonged the survival of mice.